The molecular mechanisms for hormone-resistant prostate cancer progression still remain elusive, mainly due to the limited availability of corresponding tissue. As transurethral resection (TUR) is a common palliative therapy for patients with hormone refractory prostate cancer (HRPC) who have subvesical obstruction, we aimed to demonstrate that TUR samples can be used to identify significantly affected biological pathways during the switch to HRPC using oligonucleotide microarray analysis. Among the most significantly deregulated pathways in HRPC, we observed an induction of oxidative phosphorylation and a repression of cytoskeletal components.
Introduction
Carcinoma of the prostate is the most common malignancy in males and the second leading cause of cancerrelated deaths in the United States and Europe. 1 Since about 50 years, treatment of advanced prostate cancer (PCA) is based on hormone ablation therapy. Although this treatment shows initial response rates of up to 80%, almost all patients develop hormone refractory prostate cancer (HRPC) within a median time of 15 months.
Research on HRPC was mainly focused on the androgen signalling pathway. Amplification, deregulation or mutations of the androgen receptor, its coactivators or the 5-a reductase facilitates the development of androgen receptor hypersensitivity and aberrant reaction to androgens and anti-androgens. 2 In addition, the epidermal growth factor or insulin-like growth factor-1 receptor tyrosine kinase pathways as well as the overexpression of HER-2/neu have been shown to activate the androgen receptor in the absence of an androgen receptor ligand in vitro. 3, 4 Other signalling pathways like the interleukin 6 or the transforming growth factor-b pathway have been reported to be induced in androgen-independent PCA in model systems. 5 Microarrays have been proven to be a useful tool in the discovery of molecular mechanisms of PCA and lead to the identification of common gene expression signatures of neoplastic transformation and progression. 6 However, very few microarray studies have been performed to analyse HRPC in humans. 7, 8 The limited availability of the corresponding tissue is a major problem in the research of HRPC. If patients are hormone refractory without having had a radical prostatectomy (RP), progression frequently occurs locally as well as at distant sites (bone and lymph nodes). Patients with local progression then suffer from infravesical obstruction due to tumour growth. In these patients a so-called 'palliative' transurethral resection (TUR) of the tumour often helps to regain a normal roiding.
Up to now, microarray analysis was focused on the use of biopsy material. Major problems with biopsies are the small amount of tissue material that needs a high degree of RNA amplification steps to be useful for microarray studies as well as the difficulty to characterize the tumour type and tumour content in parallel in the same biopsy that is subject to RNA isolation. TUR could potentially be useful to obtain sufficient amounts of tissue from HRPC patients for genetic analysis and allows a more accurate characterization of the tumour for further RNA analysis. However, during TUR, blood vessels are cauterized with electric current, which might interfere with RNA-based analysis methods as RNA is known to be instable.
In this study our first aim was to analyse the RNA quality of TUR samples and their suitability in gene expression profiling experiments. Second, we aimed to demonstrate the usefulness of TUR samples in microarray experiments by evaluating significantly affected metabolic or signal transduction pathways in HRPC compared to localized/hormone-sensitive PCA.
Materials and methods

Tissue samples
RP specimens and TUR samples were obtained with informed consent from patients with localized PCA and HRPC as well as benign prostatic hyperplasia (BPH), respectively ( Table 1) . Patients were treated at the Department of Urology, Klinikum Kassel GmbH, and were either candidates for curative surgical treatment (RP) or showed intravesical obstruction due to BPH or local progression of HRPC. Thus, palliative TUR was indicated in HRPC patients. After macroscopic analysis, TUR chips were cut into two sections. One section was subject to histological analysis (tumour type, percentage of tumour cells and gleason score) by a board-certified pathologist (PM), while the other section was immediately snap-frozen and further used for RNA isolation (Table 1) . Only PCA samples with at least 70% tumour cell content (or hyperplastic cells in the case of BPH) were used for RNA isolation. The time between surgery/ TUR and tissue storage in liquid nitrogen was less than 20 min.
Early HRPC was defined as resistance to complete androgen blockade (CAB) before a withdrawal of the anti-androgen. Late HRPC samples were defined according to the criteria of Scher et al., 9 that is, patients with resistance to androgen ablation therapy including antiandrogen withdrawal. For patient 132, localized PCA was diagnosed and a RP was first conducted. For this patient, TUR material was secondarily derived extracorporally from the prostatectomy resectate in order to compare tissue of the same patient obtained by open surgery as opposed to TUR (intraindividual control). TUR samples of this patient containing either PCA or BPH were used for further analysis. Patients 193 and 121 were sensitive to luteinizing hormone-releasing hormone (LHRH) treatment at the time point of TUR. Patient 58 showed a partial response to CAB.
Experimental design
The study was conducted in two phases: the aim of phase I was to determine the minimum RNA quality criteria for microarray analysis. RNA quality parameters were determined using the 2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA). The RNA quality parameters area under curve (AUC), 28S/18S rRNA ratio and the RNA integrity number (RIN) were compared to the following standard control parameters on the HG-FOCUS oligonucleotide microarrays (Affymetrix Inc., Santa Clara, CA, USA): background, noise, scaling factor, % present calls, and the 3 0 /5 0 RNA ratios of the 18S rRNA and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The RNA quality of a sample was defined to be unacceptable if a value was below the 1.5-fold interquartile range of the microarray control parameters or if background or noise were above the recommended maximums of 200 and 5, respectively. In addition, a comparison to RNA quality parameters derived from radical prostatectomies was performed. Due to the standardized RNA isolation protocol, we estimated a minimum of six TUR samples and six RP samples from different patients to be sufficient to calculate a statistical difference in each RNA quality parameter with a type I error of 5%.
The usefulness of TUR samples should be shown in a phase II where the expression profiles of HRPC patients with any stage of CAB resistance were to be compared to androgen-dependent PCA. We calculated a minimum sample size of seven patients per group assuming a type I error of 5%, a power of 80% and a fold change of two as 
RNA isolation
The amount of RNA was measured with the NanoDrop ND-1000 spectrophotometer. Fresh-frozen tissue (30-40 mg) was homogenized in 600 ml Trizol lysis buffer with an (S25-8G) UltraTurrax T25 basic and incubated for 5 min at room temperature. After chloroform extraction, the RNA was precipitated by isopropanol from the liquid phase. The RNA pellet was re-suspended in a final volume of 30 ml diethyl pyrocarbonate-treated H 2 O. Qiagen RNeasy Mini Protocol (3rd edition) for RNA clean up was performed with an 15 min DNase digestion step with 10 ml DNase I stock solution.
Probe generation and sample analysis
One microgram of RNA was used for cRNA generation using the RiboAmp OA RNA 2 Round Amplification kit (Arcturus Engineering, Mountain View, CA, USA). Twenty micrograms of RNA were used for in vitro transcription followed by labelling with the GeneChip Expression 3 0 -Amplification Reagents for IVT-labelling (Affymetrix Inc.) according to manufacturer's instructions. 10 micrograms of the labelled probe were hybridized to Affymetrix HG-Focus chip (Affymetrix Inc.) as described in the Affymetrix GeneChip Expression Analysis Technical Manual 701021 Rev.3. GeneChip washing occurred in the GeneChip Fluidics Station 400 using the Midi_euk2v3-protocol for washing. Scanning was performed with the Agilent GeneArray Scanner (Agilent Technologies Inc., Santa Clara, CA, USA).
We used five biological replicates of patient 125 (HRPC_125A-E) and four biological replicates of patient 132 where the same RNA isolation protocol was performed for different TUR chips. We analysed two technical replicates for patients HRPC_58 (HRPC_58A, HRPC_58B), HRPC_126 (HRPC_126A, HRPC_126B), HRPC_125 (HRPC_125C1, HRPC_125C2) and PCA_17, where the performance of the amplification and labelling protocol was analysed starting from the same batch of RNA.
Data analysis
The comparison of RNA quality scores from TUR material with samples obtained by RP was performed using the Wilcoxon test.
The calculation of a normalized gene expression matrix from the Affymetrix Chips was performed with the RMA algorithm 10 using the quantile normalization method. Normalization was controlled by box plot and scatter plot analysis as well as with MVA plots. All transcripts with a present (or marginal) call according to the MAS5 software (Affymetrix Inc.) of X80% in at least one of the groups to be compared were selected.
Bioinformatic analysis of the gene expression matrices was performed with the bioconductor packages on R version 2.1.1.
To distinguish between the technical effect (TUR versus RP samples) and the biological effect (PCA samples versus HRPC samples), we assessed the influence of technical and biological effects by using the global testing algorithm ANCOVA, which is based on a two-way layout linear model. 11 After the elimination of 702 genes specifically deregulated due to the technical effect (qo0.1), the biological effect corrected for the technical effect was still highly significant (Po0.001)-whereas the technical effect was not significant anymore.
Hybrid hierarchical clustering of samples and subsequent bootstrap analysis (1000 Â ) for cluster stability was performed using the HOPACH package 12 based on an expression matrix corrected for the TUR-specific genes.
For the identification of significantly affected biological pathways between HRPC and PCA samples, we applied the global test algorithm 13 on the expression matrix of 1553 transcripts (corrected for the TUR effect). Nine PCA samples (all localized PCA and hormonesensitive PCA samples with the exception of PCA_58) were compared with all seven early-and late-stage HRPC samples (Table 1 ). Only pathways with at least four deregulated genes and a P-value per pathway of o0.05 were considered. P-values were corrected using the method of Benjamini and Hochberg. 14 The data have been deposited at the public repository GEO (www.ncbi.nlm.nih.gov/geo/accession number GSE5377).
Results
RNA quality of TUR samples
First, we sought to analyse if TUR samples can provide RNA of good quality. TUR samples had a minimum size of approximately 1 Â 0.5 cm, showed a tumour content of at least 70% and did not exceed a 20 min time frame from surgery to freezing.
We isolated RNA of TUR samples from seven HRPC patients, three patients with locally advanced PCA, three BPH patients and one patient with localized PCA. Patients characteristics are shown in Table 1 . We measured the 28S/18S rRNA ratio, the AUC of the 28S and 18S rRNA peaks and the RIN of each of the RNA preparations derived from one TUR sample using the Figure 1 . The rRNA peaks were clearly visible for all samples. The RNA of all TUR samples had a 28/18S ratio X0.8 with a median ratio of 1.2 ( Figure 2a) . The RNA of all but three TUR chip preparations (HRPC_120, HRPC_125_E and HRPC_125_C) showed an AUC X10% with a median of 15.6 ( Figure 2b) . Finally, the median RIN value was 7.25 with one sample (HRPC_120) showing a RIN value below 6.2 ( Figure 2c ).
Performance of TUR samples on HG-FOCUS oligonucleotide chips
We continued to hybridize the RNA of the 14 patients on HG-FOCUS microarrays (Affymetrix Inc.). In order to assess the robustness of the protocol, we included biological (multiple TUR chips of the same patient) as well as technical replicates (multiple labelled probes of the same RNA). Successful normalization using the RMA algorithm was verified by box plot and scatter plot analysis (data not shown).
As quality control measurements, we evaluated the background, noise, scaling factor and percent present on HG-FOCUS arrays. Background and noise were below the recommended maximums of 200 and 5, respectively. The median present call percentage was 41.5% ( Figure 2) .
To investigate the behaviour of the technical and biological replicates, the Pearson's correlation coefficients of the individual groups were compared. The correlation coefficients of all HRPC samples varied between 0.88 and 0.98. The lowest correlation coefficients of biological replicates and technical replicates were 0.96 and 0.98, respectively.
In summary, we determined that TUR of the prostate from HRPC patients provides RNA of sufficient yield and quality for oligonucleotide chip analysis.
Comparison of TUR samples with sample preparations of RP
Most of the localized prostate carcinoma samples (PCA) were derived from RP samples and not from TUR chips. Therefore, we sought to examine whether there is a significant difference between the RNA preparations between TUR samples and RP samples. For this purpose, we compared the RNA quality from 6 RP samples with 14 TUR samples from different patients. RNA isolation and probe generation was performed with the same protocol. The result is shown in Figure 2 . Although RNA preparations from TUR samples gave reasonable chip results, we found significant differences (Po0.05) between both preparation types for the AUC (Po0.002) and RIN (P ¼ 0.028). However, no significant differences could be observed for the 28S/18S rRNA ratio, background, noise, scaling factors, percent present calls and the 3 0 /5 0 ratios of 18S rRNA or GAPDH transcripts. In addition, no differences in the overall 3 0 /5 0 ratio of all transcripts on a chip could be observed using RNA degradation plots (data not shown).
Cluster analysis of BPH, PCA and HRPC samples
In the next step, we were interested in an unsupervised cluster analysis of BPH, PCA and HRPC samples based on their gene expression patterns. Clustering was performed on 2297 genes and 20 patients showing transcripts with X80% present or marginal calls in at least one group. In case replicate samples existed for individual patients, we calculated the average signal intensity per patient for each transcript. From patient 132, we obtained two types of TUR samples that were analysed separately: the first one contained more than 95% of prostate carcinoma and the second contained exclusively BPH.
We used the HOPACH clustering method, which combines the strengths of both partitioning and agglomerative clustering methods. 12 In addition, we assessed the stability of the clusters using a bootstrap analysis. Cluster results are shown in Figure 3 .
In total, we can distinguish between four clusters: a BPH cluster, a PCA cluster, a mixed cluster of PCA and HRPC samples, and HRPC cluster. Interestingly, the BPH sample of patient 132 does not fit into the BPH cluster but groups together with the PCA sample of patient 132 in the PCA cluster. The three HRPC samples that appear together with four PCA samples show resistance to CAB (early HRPC group). Members of the pure HRPC cluster (red) were withdrawn from CAB therapy due to disease progression (late HRPC) or showed advanced disease progression under CAB therapy (HRPC_269). Gleason score, age and RNA quality were excluded as a reason for HRPC group separation. 
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In summary, unsupervised clustering of expression profiles from BPH, PCA and HRPC samples revealed biological differences between these disease types as well as between individual HRPC subgroups.
Identification of significantly deregulated biological pathways in HRPC in comparison to untreated and hormone-sensitive PCA Our final aim was to verify the utility of our protocol to identify significantly deregulated metabolic and signalling pathways in HRPC compared to localized/hormone-sensitive PCA. We compared nine PCA samples (all PCA samples of Table 1 except of sample PCA_58 since this patients showed already resistance to LHRH treatment) with all seven HRPC samples shown in Table 1 . We applied the global test algorithm on the expression matrix containing 1553 genes already corrected for the TUR-specific genes. 13 This test allows groups of genes to be compared because the test gives one P-value for the group, not a P-value for each gene.
We then identified 30 pathways significantly deregulated between HRPC and PCA samples (Pp0.05). As can be seen from Table 2 , among the most significantly deregulated biological pathways (corrected for the total amount of available genes per pathway on the microarray) we could identify the proteasome as well as oxidative phosphorylation and adenosine triphosphate (ATP) synthesis. The deregulated genes involved in oxidative phosphorylation and ATP synthesis such as 
Discussion
The strong limitation of sufficient amounts of prostate tissues from patients with HRPC is one of the bottlenecks in the current research of PCA. Up to now, prostate material was derived from prostatectomies or biopsies for RNA analysis. In this study, we show that samples derived by TUR of the prostate are suitable for RNA-based research methods including oligonucleotide microarrays, when collected and prepared under standardized conditions. This includes a detailed histopathological analysis, the use of samples with a minimum percentage of tumour cells (70%), a maximum time frame between surgery and tissue freezing (20 min) as well as the control of the RNA quality. This gives rise to the possibility to perform clinical trials on a larger set of patients to identify novel therapeutic concepts in HRPC.
RNAs with an AUC equal or larger than 10%, a 28S/ 18S rRNA ratio equal or larger than 0.8 and an RIN of larger than 6 showed no significant differences in the hybridization behaviour between TUR samples and RP samples according to the percentage of detectable transcripts, the scaling factor, noise, background and the 3 0 /5 0 ratios of internal chip controls. The correlation coefficients between gene expression patterns of technical and biological replicates were very high and demonstrated the robustness of the entire protocol.
Among the different possibilities to measure the RNA quality, we found the AUC and the RIN to be the most sensitive criteria to exclude low-quality RNA. With respect to these criteria, we observe a significant difference in the RNA quality between TUR and RP samples with higher AUC rates and RIN numbers in the RNA preparations of RP samples.
It was possible to distinguish BPH, PCA and late HRPC patients by clustering of patients based on their gene expression profiles, without prior knowledge of the histopathology or the clinical diagnosis. However, based on global gene expression clustering, a subset of the localized PCA patients clusters together with patients resistant to CAB. It is tempting to speculate whether this subset of PCA patients has a worse clinical outcome compared to the localized PCA patients that cluster with the hormone-sensitive PCA patients. This might especially hold true for patient 11 who even shows an affinity to the late HRPC cluster (resistance to androgen ablation therapy including antiandrogen withdrawal) according to the determination of the cluster stability based on a bootstrap analysis. A prospective clinical follow-up of these patients will determine whether these hormone-naïve patients have poorer outcomes than those hormone-naïve patients who do not cluster with the HRPC group.
Our gene expression clustering results confirmed the 'cancer field effect' described by Yu et al., 15 meaning that non-tumour cells adjacent to tumour cells show already a substantially altered gene expression pattern compared to non-tumour cells from tumour-free control tissues. From patient 132, we isolated BPH TUR material without tumour cells and PCA TUR samples containing 95% tumour cells. Both samples clustered in the PCA cluster.
The investigation of significantly deregulated metabolic and signalling pathways between PCA and HRPC revealed a strong induction of genes involved in oxidative phosphorylation in HRPC. This is noteworthy since it has been reported that cancer reduces the ATP-producing function of oxidative phosphorylation and causes a compensatory increase in glycolytic ATP production. 16, 17 A switch back to oxidative phosphorylation would allow a higher rate of ATP generation in hormone-resistant PCA cells, providing them a survival benefit.
Conclusions
In summary, we conclude that samples derived from TUR can be used for microarray analysis. Favourable experimental designs would include experiments dealing with TUR samples only such as HRPC subgroup analysis, the analysis of the mechanism of action of drugs or the screening for cytotoxic effects of drugs. At the expense of loosing information (by dropping TURspecific genes) and by enhanced statistical study design, it is also possible to analyse biological effects based on samples derived from different resection techniques.
